Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheter Ablation | 26 | 2022 | 115 | 3.180 |
Why?
|
| Atrial Fibrillation | 25 | 2025 | 411 | 2.370 |
Why?
|
| Atrial Appendage | 6 | 2025 | 24 | 0.950 |
Why?
|
| Pulmonary Veins | 6 | 2021 | 20 | 0.620 |
Why?
|
| Anticoagulants | 5 | 2022 | 143 | 0.590 |
Why?
|
| Thrombosis | 2 | 2025 | 88 | 0.520 |
Why?
|
| Heart Atria | 5 | 2018 | 84 | 0.490 |
Why?
|
| Treatment Outcome | 24 | 2025 | 3618 | 0.480 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2011 | 73 | 0.440 |
Why?
|
| Defibrillators, Implantable | 2 | 2011 | 44 | 0.420 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2011 | 103 | 0.400 |
Why?
|
| Heart Diseases | 3 | 2025 | 124 | 0.340 |
Why?
|
| Preoperative Care | 3 | 2015 | 128 | 0.320 |
Why?
|
| Middle Aged | 25 | 2025 | 12703 | 0.300 |
Why?
|
| Kidney Diseases | 1 | 2011 | 249 | 0.290 |
Why?
|
| Postoperative Complications | 5 | 2016 | 849 | 0.270 |
Why?
|
| Humans | 37 | 2025 | 34475 | 0.270 |
Why?
|
| Aged | 19 | 2025 | 10999 | 0.260 |
Why?
|
| Thromboembolism | 2 | 2019 | 38 | 0.260 |
Why?
|
| Intraoperative Complications | 3 | 2018 | 62 | 0.260 |
Why?
|
| Female | 27 | 2025 | 21491 | 0.250 |
Why?
|
| Male | 27 | 2025 | 20697 | 0.250 |
Why?
|
| Device Removal | 3 | 2023 | 44 | 0.250 |
Why?
|
| Time Factors | 11 | 2019 | 2352 | 0.250 |
Why?
|
| Echocardiography, Transesophageal | 5 | 2022 | 61 | 0.240 |
Why?
|
| Esophageal Fistula | 2 | 2016 | 11 | 0.230 |
Why?
|
| Patient Discharge | 2 | 2023 | 214 | 0.230 |
Why?
|
| Stroke Volume | 3 | 2015 | 440 | 0.220 |
Why?
|
| Thrombectomy | 1 | 2025 | 75 | 0.220 |
Why?
|
| Stroke | 2 | 2019 | 700 | 0.200 |
Why?
|
| Prospective Studies | 9 | 2020 | 2461 | 0.190 |
Why?
|
| Tachycardia, Ventricular | 2 | 2016 | 26 | 0.190 |
Why?
|
| Warfarin | 2 | 2015 | 35 | 0.190 |
Why?
|
| Risk Factors | 10 | 2019 | 4136 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2015 | 67 | 0.180 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 2366 | 0.180 |
Why?
|
| Esophagus | 2 | 2016 | 30 | 0.180 |
Why?
|
| Retrospective Studies | 7 | 2023 | 3812 | 0.180 |
Why?
|
| Hospitalization | 1 | 2023 | 500 | 0.160 |
Why?
|
| Body Surface Potential Mapping | 2 | 2018 | 14 | 0.150 |
Why?
|
| Heart Rate | 2 | 2018 | 372 | 0.150 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 5 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2021 | 1910 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 245 | 0.140 |
Why?
|
| Prevalence | 4 | 2017 | 1034 | 0.140 |
Why?
|
| Heart Conduction System | 2 | 2015 | 80 | 0.130 |
Why?
|
| Electrocardiography | 2 | 2014 | 657 | 0.130 |
Why?
|
| Thyroid Hormones | 1 | 2017 | 8 | 0.130 |
Why?
|
| Feasibility Studies | 3 | 2025 | 323 | 0.130 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2016 | 19 | 0.130 |
Why?
|
| Cicatrix | 1 | 2016 | 41 | 0.120 |
Why?
|
| Hot Temperature | 1 | 2016 | 89 | 0.120 |
Why?
|
| Pericardial Effusion | 1 | 2016 | 9 | 0.120 |
Why?
|
| Sinoatrial Node | 1 | 2015 | 4 | 0.120 |
Why?
|
| Tachycardia, Sinus | 1 | 2015 | 5 | 0.120 |
Why?
|
| Balloon Occlusion | 1 | 2016 | 38 | 0.120 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2015 | 65 | 0.120 |
Why?
|
| Recurrence | 4 | 2021 | 295 | 0.120 |
Why?
|
| Survival Rate | 3 | 2015 | 925 | 0.110 |
Why?
|
| Atrial Flutter | 1 | 2015 | 20 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 137 | 0.110 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 934 | 0.110 |
Why?
|
| Amiodarone | 1 | 2014 | 5 | 0.110 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 17 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2015 | 83 | 0.110 |
Why?
|
| International Normalized Ratio | 2 | 2015 | 8 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 138 | 0.110 |
Why?
|
| Migraine Disorders | 1 | 2015 | 69 | 0.110 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 60 | 0.100 |
Why?
|
| Comorbidity | 2 | 2016 | 596 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2014 | 438 | 0.100 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 287 | 0.100 |
Why?
|
| Heart Failure | 2 | 2011 | 780 | 0.100 |
Why?
|
| Exercise Test | 1 | 2014 | 247 | 0.100 |
Why?
|
| Incidence | 5 | 2015 | 1289 | 0.100 |
Why?
|
| Stents | 1 | 2014 | 167 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2013 | 38 | 0.090 |
Why?
|
| Adult | 7 | 2015 | 10015 | 0.090 |
Why?
|
| Laser Therapy | 1 | 2013 | 56 | 0.090 |
Why?
|
| United States | 6 | 2019 | 4267 | 0.090 |
Why?
|
| Pacemaker, Artificial | 1 | 2013 | 42 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 922 | 0.090 |
Why?
|
| Equipment Design | 3 | 2021 | 192 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 803 | 0.090 |
Why?
|
| Life Style | 1 | 2014 | 418 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 1078 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 306 | 0.090 |
Why?
|
| Quality of Life | 2 | 2015 | 1032 | 0.090 |
Why?
|
| Sodium Channels | 1 | 2011 | 16 | 0.090 |
Why?
|
| Robotics | 1 | 2012 | 135 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 315 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2011 | 155 | 0.080 |
Why?
|
| Prognosis | 4 | 2016 | 1603 | 0.080 |
Why?
|
| Enoxaparin | 1 | 2010 | 21 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 4151 | 0.080 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2009 | 13 | 0.080 |
Why?
|
| Muscle, Smooth | 1 | 2010 | 152 | 0.080 |
Why?
|
| Muscle Contraction | 1 | 2010 | 183 | 0.080 |
Why?
|
| Myocardial Infarction | 2 | 2016 | 515 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 304 | 0.070 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2009 | 64 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 350 | 0.070 |
Why?
|
| Ventricular Fibrillation | 1 | 2008 | 7 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2009 | 509 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 59 | 0.070 |
Why?
|
| Age Factors | 1 | 2011 | 1262 | 0.070 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2018 | 28 | 0.060 |
Why?
|
| Fluoroscopy | 2 | 2017 | 44 | 0.060 |
Why?
|
| Body Temperature | 1 | 2006 | 23 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2009 | 441 | 0.060 |
Why?
|
| Registries | 2 | 2022 | 328 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2016 | 1506 | 0.060 |
Why?
|
| North Carolina | 1 | 2010 | 1612 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 84 | 0.060 |
Why?
|
| Texas | 2 | 2016 | 40 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 230 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2021 | 57 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 100 | 0.040 |
Why?
|
| Dobutamine | 1 | 2020 | 71 | 0.040 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2019 | 5 | 0.040 |
Why?
|
| Phrenic Nerve | 1 | 2018 | 5 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 50 | 0.030 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2016 | 3 | 0.030 |
Why?
|
| Young Adult | 2 | 2015 | 2825 | 0.030 |
Why?
|
| Stethoscopes | 1 | 2016 | 1 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2016 | 57 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 96 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2016 | 45 | 0.030 |
Why?
|
| Premedication | 1 | 2016 | 17 | 0.030 |
Why?
|
| Echocardiography | 1 | 2017 | 202 | 0.030 |
Why?
|
| Adolescent | 2 | 2015 | 3799 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 565 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 86 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 131 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 149 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 14 | 0.030 |
Why?
|
| Telemetry | 1 | 2015 | 30 | 0.030 |
Why?
|
| Isoproterenol | 1 | 2014 | 19 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 56 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2014 | 36 | 0.030 |
Why?
|
| Action Potentials | 1 | 2015 | 220 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 337 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 755 | 0.030 |
Why?
|
| Patient Selection | 1 | 2015 | 291 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 583 | 0.020 |
Why?
|
| Reoperation | 1 | 2014 | 265 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2014 | 161 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 849 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1607 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 191 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 41 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 66 | 0.020 |
Why?
|
| Alleles | 1 | 2011 | 257 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 924 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2010 | 46 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2012 | 349 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2009 | 168 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 1209 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 612 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2008 | 207 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 819 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 703 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 325 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 808 | 0.020 |
Why?
|
| Child | 1 | 2013 | 2613 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2006 | 24 | 0.010 |
Why?
|